March 10th 2023
Soligenix has requested a Type A meeting with the FDA to get clarity around the item needed to complete the new drug application of SGX301 for patients with early-stage cutaneous T-cell lymphoma.
Addition of Bortezomib Shows Efficacy/Safety in Waldenström's Macroglobulinemia
February 15th 2023A phase 3 trial of bortezomib, dexamethasone, rituximab, and cyclophosphamide shortened the median time to first response and increased the number of patients with Waldenström's macroglobulinemia.
Read More
Perez on Real-World Pola-BR Treatment Outcomes in Patients with R/R LBCL
January 16th 2023In an interview with Targeted Oncology, Ariel Perez, MD, explained the outcomes of patients with R/R large B-cell lymphoma who were treated with Pola-BR in the real-world setting, and the key takeaways from a single-institution study.
Read More
Addition of Polatuzumab to R-CHOP Improves Outcomes for Patients With DLBCL
January 10th 2023In an interview with Targeted Oncology, Gustavo Fonseca, MD, FACP, discussed the positive health-related quality of life findings in patients with diffuse large B-cell lymphoma from the POLARIX study.
Read More
Glofitamab Leads to Durable Complete Remissions in Relapsed/Refractory LBCL
January 6th 2023In an interview with Targeted Oncology, Cyrus M. Khan, MD, further discussed the background of the phase 1/2 trial and the potential use of glofitamab for patients with large B-cell lymphoma in the future.
Read More
HD-ASCT Shows Longer Survival Vs Non-Myeloablative Chemoimmunotherapy in Primary CNS Lymphoma
December 13th 2022An extended progression-free survival and 54% reduction in the risk of death was shown with high-dose chemotherapy autologous stem cell transplantation consolidation therapy vs non-myeloablative chemoimmunotherapy in patients with primary central nervous system lymphoma.
Read More
Lenalidomide/ Rituximab Extends 5-Year PFS on R/R Indolent Non-Hodgkin Lymphoma
December 11th 2022Five-year follow up results from the phase 3 AUGMENT trial show that lenalidomide plus rituximab produced enhanced progression-free survival in patients with relapsed/refractory indolent non-Hodgkin lymphoma.
Read More
ECHELON-1 Trial of Brentuximab Vedotin Improves OS in Classical Hodgkin Lymphoma
December 7th 2022In an interview with Targeted Oncology, David J. Straus, MD, discussed the newest data of the ECHELON-1 trial which he presented at the National Comprehensive Cancer Network 2022 Annual Congress: Hematologic Malignancies.
Read More
Ultra-Low Dose of Radiation Shows Promise in Orbital Indolent B-Cell Lymphomas
November 28th 2022In an interview with Targeted Oncology, Chelsea C. Pinnix discussed the results of a phase 2 study and how these promising results will shift the treatment paradigm of patients with orbital indolent B-cell lymphoma.
Read More
FDA Grants Priority Review to Subcutaneous Epcoritamab for Previously Treated R/R LBCL
November 21st 2022Based on positive findings from the phase 2 pivotal EPCORE NHL-1, the FDA will conduct a speedy review of the biologics license application for subcutaneous epcoritamab for the treatment of patients with relapsed/refractory large B-cell lymphoma after 2 or more lines of systemic therapy an granted it priority review.
Read More
FDA Approves Brentuximab Vedotin for Pediatric Patients With High-Risk Hodgkin Lymphoma
November 10th 2022Based on results from the phase 3 AHOD1331 trial, the FDA has approved brentuximab vedotin in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide in pediatric patients with high-risk classical Hodgkin lymphoma.
Read More
FDA Advises Against an Approval Filing for Camidanlumab Tesirine to Treat R/R HL
November 10th 2022The FDA has advised ADC Therapeutics that a randomized phase 3 confirmatory study is needed to support a future FDA approval for camidanlumab tesirine as treatment of relapsed or refractory Hodgkin lymphoma.
Read More